Company news
ChemoCentryx Inc. news in 2021
ChemoCentryx Inc.'s news releases, calls and decks from 2021, newest first.
ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights
November 8, 2021
ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer
October 10, 2021
ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis
October 7, 2021
ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis
September 26, 2021
ChemoCentryx Reports Second Quarter 2021 Financial Results and Recent Highlights
August 8, 2021
ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis
July 5, 2021
ChemoCentryx Announces Abstract on Avacopan in ANCA-Associated Vasculitis Selected as One of the Ten Best Abstracts at the ERA-EDTA Congress
June 7, 2021
ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis
May 5, 2021
ChemoCentryx Reports First Quarter 2021 Financial Results and Recent Highlights
April 28, 2021
ChemoCentryx to Host Virtual R&D Day on April 14, 2021
April 6, 2021
ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors
March 7, 2021
ChemoCentryx Appoints Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer
February 23, 2021
ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
February 16, 2021